Literature DB >> 1772142

Achievement of spermatogenesis and genital tract maturation in hypogonadotropic hypogonadic subjects during long term treatment with gonadotropins or LHRH.

I Mastrogiacomo1, R G Motta, S Botteon, G Bonanni, M Schiesaro.   

Abstract

15 subjects with Hypogonadotropic Hypogonadism (HH) were treated with either gonadotropins (13 cases) or pulsatile subcutaneous Luteinizing Hormone Releasing Hormone (LHRH) (2 cases) for up to 42 months, to study the effects of therapy step by step. The following results were obtained: (A) In postpubertal HH (5 cases = Group A), therapy brought about onset of spermatogenesis within 3 months and its normalization within 6 months. In HH of prepubertal onset (10 cases = Group B), spermatogenesis started within 9 to 21 months and became normal in only 3 cases after at least 18 months. The best sperm counts were obtained in Group A in the third month of treatment (41.75 +/- 43.68 mil./ml) and in Group B in the 36th month (14.87 +/- 17.06 mil./ml). Sperm motility was normal in the majority of the cases in Group A from the beginning but did not become normal in Group B. (B) Seminal fructose and zinc were normal from the beginning of therapy in 66% of the cases in both groups. Zinc became normal in 100% within 3 months in Group A, in Group B within 18. Carnitine was normal in 50% of cases in both groups, contemporaneous with sperm appearance. Transferrin was normal in Group A after appearance of spermatozoa, but in Group B never became normal. (C) We hypothesize that the recovery of fertility passes through the following stages: (1) Functional recovery of Leydig cells, followed by seminal vesicles and prostate. (2) Recovery of epididymal function, which probably implies beginning of the tubular function. Recovery of Sertoli cell function occurs with more difficulty.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772142     DOI: 10.1111/j.1439-0272.1991.tb02561.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  4 in total

Review 1.  Follicle-stimulating hormone treatment in normogonadotropic infertile men.

Authors:  Daniela Valenti; Sandro La Vignera; Rosita A Condorelli; Rocco Rago; Nunziata Barone; Enzo Vicari; Aldo E Calogero
Journal:  Nat Rev Urol       Date:  2012-12-11       Impact factor: 14.432

2.  Testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) in hypogonadotropic hypogonadism with persistent azoospermia after hormonal therapy.

Authors:  Marcos Meseguer; Nicolás Garrido; José Remohí; Antonio Pellicer; Manuel Gil-Salom
Journal:  J Assist Reprod Genet       Date:  2004-03       Impact factor: 3.412

3.  A successful conception by a shift from human menopausal gonadotropin therapy to therapy with recombinant human follicular-stimulating hormone for the treatment of male hypogonadotropic hypogonadism.

Authors:  Kohei Koyama; Hiroshi Masuda; Teruo Inamoto; Naoki Segawa; Haruhito Azuma; Yoji Katsuoka
Journal:  Reprod Med Biol       Date:  2009-10-06

4.  Reduced Seminal Concentration of CD45pos Cells after Follicle-Stimulating Hormone Treatment in Selected Patients with Idiopathic Oligoasthenoteratozoospermia.

Authors:  Rosita A Condorelli; Aldo E Calogero; Enzo Vicari; Laura Mongioi'; Giovanni Burgio; Rossella Cannarella; Filippo Giacone; Linda Iacoviello; Giuseppe Morgia; Vincenzo Favilla; Sebastiano Cimino; Sandro La Vignera
Journal:  Int J Endocrinol       Date:  2014-01-14       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.